Should I buy or sell Illumina stock right now?

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 2 sell ratings, 10 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares. View ILMN analyst ratings or view top-rated stocks .

What is Illumina's stock price target for 2024?

20 brokerages have issued twelve-month target prices for Illumina's shares. Their ILMN share price targets range from $100.00 to $253.00. On average, they predict the company's share price to reach $164.65 in the next twelve months. This suggests a possible upside of 49.7% from the stock's current price. View analysts price targets for ILMN or view top-rated stocks among Wall Street analysts .

How have ILMN shares performed in 2024?

Illumina's stock was trading at $139.24 at the beginning of the year. Since then, ILMN shares have decreased by 21.0% and is now trading at $110.02. View the best growth stocks for 2024 here .

Are investors shorting Illumina?

Illumina saw a drop in short interest during the month of April. As of April 30th, there was short interest totaling 4,760,000 shares, a drop of 9.7% from the April 15th total of 5,270,000 shares. Based on an average trading volume of 1,690,000 shares, the days-to-cover ratio is presently 2.8 days. View Illumina's Short Interest .

When is Illumina's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our ILMN earnings forecast .

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) announced its earnings results on Thursday, May, 2nd. The life sciences company reported $0.09 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.05. The life sciences company earned $1.08 billion during the quarter, compared to analyst estimates of $1.05 billion. Illumina had a negative net margin of 28.71% and a positive trailing twelve-month return on equity of 2.31%. The business's revenue for the quarter was down 1.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.08 EPS. Read the conference call transcript .

What ETFs hold Illumina's stock?

ETFs with the largest weight of Illumina (NASDAQ:ILMN) stock in their portfolio include VanEck Biotech ETF (BBH) , Global X Telemedicine & Digital Health ETF (EDOC) , Global X Genomics & Biotechnology ETF (GNOM) , First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , Tema Oncology ETF (CANC) , Principal Healthcare Innovators ETF (BTEC) and iShares Biotechnology ETF (IBB) .

What guidance has Illumina issued on next quarter's earnings?

Illumina issued an update on its FY 2024 earnings guidance on Tuesday, April, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.4 billion-$4.4 billion, compared to the consensus revenue estimate of $4.5 billion.

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com . Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA) , Alibaba Group (BABA) , Tesla (TSLA) , Netflix (NFLX) , Walt Disney (DIS) , PayPal (PYPL) , Salesforce (CRM) , Adobe (ADBE) , Visa (V) and Micron Technology (MU) .

Who are Illumina's major shareholders?

Illumina's stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (3.60%), WCM Investment Management LLC (2.12%), Bank of New York Mellon Corp (1.78%), Findlay Park Partners LLP (0.46%), Chevy Chase Trust Holdings LLC (0.33%) and Swiss National Bank (0.30%). Insiders that own company stock include Aimee L Hoyt , Alexander Aravanis , Charles Dadswell , Jacob Thaysen, Jay T Flatley , Phillip G Febbo , Susan H Tousi and Susan H Tousi . View institutional ownership trends .

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Illumina have any subsidiaries?

The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Emedgene Inc., Emedgene Technologies Ltd, Enancio, Enancio SAS, Epicentre Biotechnologies, GRAIL LLC, GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV. Read More

NASDAQ:ILMN

Illumina (ILMN) Stock Price, News & Analysis

→ Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad)

Free ILMN Stock Alerts

$110.24

-1.11 (-1.00%)

(As of 01:40 PM ET)

Compare

Today's Range: $109.53
▼
$112.24
50-Day Range: $110.62
▼
$140.50
52-Week Range: $89.00
▼
$213.91

Volume: 421,906 shs
Average Volume: 1.73 million shs
Market Capitalization: $17.56 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $164.65

Get Illumina alerts:

Illumina MarketRank™ Stock Analysis

Analyst Rating: Hold
2.30 Rating Score
Upside/Downside: 49.7% Upside
$164.65 Price Target
Short Interest: Healthy
2.99% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.11
Upright™ Environmental Score
News Sentiment: 0.26
Based on 27 Articles This Week
Insider Trading: Acquiring Shares
$991,676 Bought Last Quarter
Proj. Earnings Growth: 164.84%
From $0.91 to $2.41 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.95 out of 5 stars

Medical Sector

30th out of 915 stocks

Analytical Instruments Industry

2nd out of 28 stocks

4.2

Analyst's Opinion

Consensus Rating
Illumina has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 8 buy ratings, 10 hold ratings, and 2 sell ratings.
Amount of Analyst Coverage
Illumina has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Read more about Illumina's stock forecast and price target.

5.0

Short Interest

Percentage of Shares Shorted
2.99% of the outstanding shares of Illumina have been sold short.
Short Interest Ratio / Days to Cover
Illumina has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Illumina has recently decreased by 9.68%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Illumina does not currently pay a dividend.
Dividend Growth
Illumina does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Illumina has received a 61.69% net impact score from Upright. Illumina seems to create the most significant positive value in categories "Taxes", "Jobs", and "Physical diseases". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Laboratory reagents", "DNA sequencers", and "Laboratory reagents for cells" products. See details.
Environmental Sustainability
The Environmental Impact score for Illumina is -1.11.

2.4

News and Social Media Coverage

News Sentiment
Illumina has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 27 news articles for Illumina this week, compared to 16 articles on an average week.
Search Interest
Only 17 people have searched for ILMN on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
MarketBeat Follows
15 people have added Illumina to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Illumina insiders have bought more of their company's stock than they have sold. Specifically, they have bought $991,676.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 0.17% of the stock of Illumina is held by insiders.
Percentage Held by Institutions
89.42% of the stock of Illumina is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Read more about Illumina's insider trading history.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Illumina are expected to grow by 164.84% in the coming year, from $0.91 to $2.41 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Illumina is -13.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Illumina is -13.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Illumina has a P/B Ratio of 3.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Read more about Illumina's valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Colonial Metals

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

About Illumina Stock (NASDAQ:ILMN)

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

ILMN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ILMN Stock News Headlines

May 8, 2024 | americanbankingnews.com

Illumina (NASDAQ:ILMN) Given Overweight Rating at Stephens

May 8, 2024 | americanbankingnews.com

Illumina (NASDAQ:ILMN) Price Target Cut to $176.00

May 10, 2024 | Crypto 101 Media (Ad)

The Crypto 9-5 Escape Plan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

May 7, 2024 | bizjournals.com

Biotech giant lays groundwork for divestiture of early-cancer test maker Grail

May 7, 2024 | benzinga.com

Illumina Unusual Options Activity For May 07

May 7, 2024 | msn.com

Illumina picks spin-off option for Grail divestment

May 7, 2024 | americanbankingnews.com

StockNews.com Lowers Illumina (NASDAQ:ILMN) to Hold

May 6, 2024 | seekingalpha.com

Illumina: Expect A Slow Rebound

May 10, 2024 | Crypto 101 Media (Ad)

The Crypto 9-5 Escape Plan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

May 6, 2024 | prnewswire.com

Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL

May 6, 2024 | fool.com

Illumina's Q1 Earnings Beat Estimates

May 6, 2024 | americanbankingnews.com

Q3 2024 EPS Estimates for Illumina, Inc. Cut by Analyst (NASDAQ:ILMN)

May 5, 2024 | americanbankingnews.com

Illumina (NASDAQ:ILMN) PT Raised to $128.00 at Robert W. Baird

May 4, 2024 | markets.businessinsider.com

Beyond The Numbers: 6 Analysts Discuss Illumina Stock

May 4, 2024 | finance.yahoo.com

Illumina First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

May 3, 2024 | finance.yahoo.com

Illumina, Inc. (NASDAQ:ILMN) Q1 2024 Earnings Call Transcript

May 3, 2024 | uk.finance.yahoo.com

Illumina Inc (ILMN) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and ...

May 3, 2024 | prnewswire.com

Illumina To Webcast Upcoming Investor Conference

May 2, 2024 | investorplace.com

ILMN Stock Earnings: Illumina Beats EPS, Beats Revenue for Q1 2024

May 2, 2024 | markets.businessinsider.com

Illumina Inc. Q1 Earnings Summary

May 2, 2024 | finance.yahoo.com

Illumina Inc (ILMN) Q1 Earnings: Navigating Through Challenges with Mixed Results

May 2, 2024 | reuters.com

Illumina reaffirms annual revenue forecast over continued sluggish demand

May 2, 2024 | prnewswire.com

Illumina Reports Financial Results for First Quarter of Fiscal Year 2024

May 1, 2024 | markets.businessinsider.com

Illumina earnings preview: what to expect

April 30, 2024 | msn.com

Garvan Institute and Illumina collaborate to transform the treatment of complex diseases

April 29, 2024 | finance.yahoo.com

Inspiring Young Minds: HRH the Princess Royal Helps Illumina Celebrate DNA Day

April 23, 2024 | finance.yahoo.com

Illumina (NASDAQ:ILMN) investors are sitting on a loss of 71% if they invested three years ago

See More Headlines

Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/02/2024
Today: 5/10/2024
Next Earnings (Estimated): 8/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Analytical instruments
Sub-Industry: Life Sciences Tools & Services
Current Symbol: NASDAQ:ILMN
CUSIP: 45232710
CIK: 1110803
Web: www.illumina.com
Phone: (858) 202-4500
Fax: 858-202-4766
Employees: 9,300
Year Founded: 1998

Price Target and Rating

Average Stock Price Target: $164.65
High Stock Price Target: $253.00
Low Stock Price Target: $100.00
Potential Upside/Downside: +47.9%
Consensus Rating: Hold
Rating Score (0-4): 2.30
Research Coverage: 20 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($8.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 122.36
P/E Growth: N/A
Net Income: $-1,161,000,000.00
Net Margins: -28.71%
Pretax Margin: -25.55%
Return on Equity: 2.31%
Return on Assets: 1.31%

Debt

Debt-to-Equity Ratio: 0.26
Current Ratio: 1.75
Quick Ratio: 1.36

Sales & Book Value

Annual Sales: $4.49 billion
Price / Sales: 3.95
Cash Flow: $3.38 per share
Price / Cash Flow: 32.91
Book Value: $36.18 per share
Price / Book: 3.08

Miscellaneous

Outstanding Shares: 159,300,000
Free Float: 158,984,000
Market Cap: $17.74 billion
Optionable: Optionable
Beta: 1.20

Social Links

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Jacob Thaysen Ph.D. (Age 49)
CEO & Director
Comp: $796.63k
Ms. Carissa L. Rollins (Age 54)
Chief Information Officer
Comp: $693.52k
Mr. Charles E. Dadswell Esq. (Age 65)
Senior VP & General Counsel
Comp: $1.03M
Dr. Joydeep Goswami M.B.A. (Age 53)
Ph.D., Advisor
Comp: $843.55k
Stephanie Campos
President
Mr. Ankur Dhingra (Age 48)
Chief Financial Officer
Mr. Kevin Carl Pegels (Age 56)
Chief of Global Operations
Mr. Scott Ericksen (Age 51)
VP & Chief Accounting Officer
Dr. Steven Barnard Ph.D.
Chief Technology Officer
Ms. Sallilyn Schwartz
Vice President of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ILMN Stock Analysis - Frequently Asked Questions

Should I buy or sell Illumina stock right now?: 20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 2 sell ratings, 10 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings or view top-rated stocks.
What is Illumina's stock price target for 2024?: 20 brokerages have issued twelve-month target prices for Illumina's shares. Their ILMN share price targets range from $100.00 to $253.00. On average, they predict the company's share price to reach $164.65 in the next twelve months. This suggests a possible upside of 49.7% from the stock's current price.
View analysts price targets for ILMN or view top-rated stocks among Wall Street analysts.
How have ILMN shares performed in 2024?: Illumina's stock was trading at $139.24 at the beginning of the year. Since then, ILMN shares have decreased by 21.0% and is now trading at $110.02.
View the best growth stocks for 2024 here.
Are investors shorting Illumina?: Illumina saw a drop in short interest during the month of April. As of April 30th, there was short interest totaling 4,760,000 shares, a drop of 9.7% from the April 15th total of 5,270,000 shares. Based on an average trading volume of 1,690,000 shares, the days-to-cover ratio is presently 2.8 days.
View Illumina's Short Interest.
When is Illumina's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our ILMN earnings forecast.
How were Illumina's earnings last quarter?: Illumina, Inc. (NASDAQ:ILMN) announced its earnings results on Thursday, May, 2nd. The life sciences company reported $0.09 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.05. The life sciences company earned $1.08 billion during the quarter, compared to analyst estimates of $1.05 billion. Illumina had a negative net margin of 28.71% and a positive trailing twelve-month return on equity of 2.31%. The business's revenue for the quarter was down 1.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.08 EPS.
Read the conference call transcript.
What ETFs hold Illumina's stock?: ETFs with the largest weight of Illumina (NASDAQ:ILMN) stock in their portfolio include VanEck Biotech ETF (BBH), Global X Telemedicine & Digital Health ETF (EDOC), Global X Genomics & Biotechnology ETF (GNOM), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust NYSE Arca Biotechnology Index Fund (FBT), Tema Oncology ETF (CANC), Principal Healthcare Innovators ETF (BTEC) and iShares Biotechnology ETF (IBB).

What guidance has Illumina issued on next quarter's earnings?: Illumina issued an update on its FY 2024 earnings guidance on Tuesday, April, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.4 billion-$4.4 billion, compared to the consensus revenue estimate of $4.5 billion.
What is Francis deSouza's approval rating as Illumina's CEO?: 496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Illumina own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).
Who are Illumina's major shareholders?: Illumina's stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (3.60%), WCM Investment Management LLC (2.12%), Bank of New York Mellon Corp (1.78%), Findlay Park Partners LLP (0.46%), Chevy Chase Trust Holdings LLC (0.33%) and Swiss National Bank (0.30%). Insiders that own company stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Jacob Thaysen, Jay T Flatley, Phillip G Febbo, Susan H Tousi and Susan H Tousi.
View institutional ownership trends.
How do I buy shares of Illumina?: Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Illumina have any subsidiaries?: The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Emedgene Inc., Emedgene Technologies Ltd, Enancio, Enancio SAS, Epicentre Biotechnologies, GRAIL LLC, GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.
Read More

This page (NASDAQ:ILMN) was last updated on 5/10/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Illumina (ILMN) Stock Price, News & Analysis

Illumina MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows